Bleeding Episodes in Patients With Haemophilia B Receiving Prophylactic Factor IX Treatment: A Systematic Review and Meta‐Analysis
Haemophilia · 2025-03 · 31 (2) · 173-186
DOI: 10.1111/hae.70006 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Haemophilia, online erschienen am 14.02.2025. Verfasst von Massimo Franchini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy. Hauptthemen laut MEDLINE: Hemophilia B, Factor IX, Hemorrhage. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Abstract (Originalsprache)
Background
Prophylaxis with coagulation factor concentrates is the mainstay of treatment in severe hemophilia A and B. Data on bleeding rates in persons with congenital haemophilia B (PwcHB) receiving prophylaxis are inconsistent.
Aim
This systematic review and meta‐analysis were aimed at assessing bleeding outcomes, including annualised bleeding rates (ABR) and the proportion of patients with zero bleeding events, in PwcHB receiving prophylaxis with plasma‐derived or recombinant FIX products with standard (rSHL) or extended half‐life (rEHL).
Methods
A systematic search was conducted using the bibliographic database Medline, Embase and Cochrane Central Register. The protocol was registered on PROSPERO (registration number: CRD42024592785).
Results
The search yielded 2440 citations and a total of 42 studies (2 randomised and 40 nonrandomised) were included in the final analysis. The pooled estimated mean (95% confidence interval [CI]) ABR was significantly lower in PwcHB treated prophylactically with rEHL FIX than in those receiving rSHL FIX products (1.29 [95% CI: 0.91, 1.66] vs. 3.12 [95% CI: 2.63, 3.62], p < 0.01). The proportion of participants with zero bleeding events was significantly higher in PwcHB treated prophylactically with rEHL FIX than in those receiving rSHL FIX (0.53 [95% CI: 0.37, 0.69] vs. 0.24 [95% CI: 0.14, 0.39], p = 0.01). The ABR did not differ according to age groups (more or less than 12 years).
Conclusion
The results of this meta‐analysis suggest that compared to standard half‐life FIX concentrates, prophylaxis with rEHL FIX products is associated with a reduction in ABR and a higher proportion of patients with no bleeding episodes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy.
- Transfusion and Immunohematology Department, Azienda Provinciale Servizi Sanitari (APSS) - Trento, Trento, Italy.
- North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
- Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
ORCID-Profile: Massimo Franchini, Samantha Pasca, Pier Mannuccio Mannucci
Zitieren
APA
Franchini, M., Pasca, S., Mengoli, C., Focosi, D., & Mannucci, P. M. (2025). Bleeding Episodes in Patients With Haemophilia B Receiving Prophylactic Factor IX Treatment: A Systematic Review and Meta‐Analysis. Haemophilia, 31(2), 173-186. https://doi.org/10.1111/hae.70006
Vancouver
Franchini M, Pasca S, Mengoli C, Focosi D, Mannucci PM. Bleeding Episodes in Patients With Haemophilia B Receiving Prophylactic Factor IX Treatment: A Systematic Review and Meta‐Analysis. Haemophilia. 2025;31(2):173-186. doi:10.1111/hae.70006
BibTeX
@article{Franchini2025,
author = {Franchini, Massimo and Pasca, Samantha and Mengoli, Carlo and Focosi, Daniele and Mannucci, Pier Mannuccio},
title = {Bleeding Episodes in Patients With Haemophilia B Receiving Prophylactic Factor IX Treatment: A Systematic Review and Meta‐Analysis},
journal = {Haemophilia},
year = {2025},
volume = {31},
number = {2},
pages = {173--186},
doi = {10.1111/hae.70006}
}
EUVIMED